Skip to main content
Journal cover image

Tryptophan degradation is associated with risk-taking propensity in methamphetamine users with treated HIV infection.

Publication ,  Journal Article
Lee, J; Lee, J-Y; Meade, CS; Cohn, M; Chahine, A; Dilworth, SE; Magidson, JF; Gouse, H; Fuchs, D; Carrico, AW
Published in: Journal of neurovirology
October 2020

Few studies have examined neuroimmune pathways that could contribute to impulsivity in people living with HIV who use substances. Eighty-four methamphetamine-using, sexual minority men with an undetectable HIV viral load were administered the Balloon Analogue Risk Task (BART), a behavioral measure of risk-taking propensity. We examined the associations between kynurenine/tryptophan ratio and phenylalanine/tyrosine ratio with BART scores using multiple linear regression. A higher kynurenine/tryptophan ratio was independently associated with greater BART scores (beta = 0.25; 95% CI = 0.05-1.23; p = 0.034). The phenylalanine/tyrosine ratio was not significantly associated with BART scores. Findings support the need for further research to elucidate the neuroimmune mechanisms linking tryptophan degradation with impulsivity to catalyze the development novel pharmacologic treatments for people living with HIV who use methamphetamine.

Duke Scholars

Published In

Journal of neurovirology

DOI

EISSN

1538-2443

ISSN

1355-0284

Publication Date

October 2020

Volume

26

Issue

5

Start / End Page

779 / 784

Related Subject Headings

  • Virology
  • Viral Load
  • Tyrosine
  • Tryptophan
  • Substance-Related Disorders
  • Risk-Taking
  • Psychological Tests
  • Phenylalanine
  • Middle Aged
  • Methamphetamine
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lee, J., Lee, J.-Y., Meade, C. S., Cohn, M., Chahine, A., Dilworth, S. E., … Carrico, A. W. (2020). Tryptophan degradation is associated with risk-taking propensity in methamphetamine users with treated HIV infection. Journal of Neurovirology, 26(5), 779–784. https://doi.org/10.1007/s13365-020-00841-4
Lee, Jared, Ji-Young Lee, Christina S. Meade, Michael Cohn, Antonio Chahine, Samantha E. Dilworth, Jessica F. Magidson, Hetta Gouse, Dietmar Fuchs, and Adam W. Carrico. “Tryptophan degradation is associated with risk-taking propensity in methamphetamine users with treated HIV infection.Journal of Neurovirology 26, no. 5 (October 2020): 779–84. https://doi.org/10.1007/s13365-020-00841-4.
Lee J, Lee J-Y, Meade CS, Cohn M, Chahine A, Dilworth SE, et al. Tryptophan degradation is associated with risk-taking propensity in methamphetamine users with treated HIV infection. Journal of neurovirology. 2020 Oct;26(5):779–84.
Lee, Jared, et al. “Tryptophan degradation is associated with risk-taking propensity in methamphetamine users with treated HIV infection.Journal of Neurovirology, vol. 26, no. 5, Oct. 2020, pp. 779–84. Epmc, doi:10.1007/s13365-020-00841-4.
Lee J, Lee J-Y, Meade CS, Cohn M, Chahine A, Dilworth SE, Magidson JF, Gouse H, Fuchs D, Carrico AW. Tryptophan degradation is associated with risk-taking propensity in methamphetamine users with treated HIV infection. Journal of neurovirology. 2020 Oct;26(5):779–784.
Journal cover image

Published In

Journal of neurovirology

DOI

EISSN

1538-2443

ISSN

1355-0284

Publication Date

October 2020

Volume

26

Issue

5

Start / End Page

779 / 784

Related Subject Headings

  • Virology
  • Viral Load
  • Tyrosine
  • Tryptophan
  • Substance-Related Disorders
  • Risk-Taking
  • Psychological Tests
  • Phenylalanine
  • Middle Aged
  • Methamphetamine